Our intention is that both paediatric and adult patients can benefit from the CEB-01 drug in their oncological treatments, prioritising the paediatric line during its development.

Our drug is currently in Clinical Phase 2a (security), and it is showing extremely promising results.

After finalising the security studies in the first 9 out of 21 patients, we will be able to reach our big objective: initiate the clinical studies with paediatric patients alongside Sant Joan de Déu Barcelona Children’s Hospital.

In order to achieve it and advance our work, your participation is essential.

Join us by sharing our project!